Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to loss of $0.48 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10.77%. A quarter ago, it was expected that this company would post a loss of $0.95 per share when it actually produced a loss of $0.79, delivering a surprise of 16.84%.Over the last four quarters, the com ...

Financial Performance - Total revenue for Q1 2024 was $37.2 million, a decrease of 20% compared to $46.5 million in Q1 2023[4] - Gross profit for Q1 2024 was $24.4 million, representing a gross margin of 65.6%, up from 64.7% in the same period last year[4] - The net loss for Q1 2024 was $16.2 million, compared to a net loss of $11.9 million in Q1 2023[7] - Net loss for the three months ended March 31, 2024, was $16.202 million, compared to a net loss of $11.942 million in the same period of 2023, reflecting a decline of 35.5%[24] - Adjusted EBITDA loss improved to $3.7 million in Q1 2024, compared to a loss of $17.3 million in Q4 2023[5] - Adjusted EBITDA improved to a loss of $3.652 million for Q1 2024, compared to a loss of $4.015 million in Q1 2023, indicating a positive trend[24] Revenue Guidance - The company expects 2024 revenue guidance of $174 million to $184 million, reflecting a growth of 5% to 11% over 2023[5] Operating Expenses - Operating expenses decreased to $33.2 million in Q1 2024, down from $38.2 million in Q1 2023[6] - Research and development expenses were reduced to $4.3 million in Q1 2024, compared to $6.5 million in the same quarter last year[7] Assets and Liabilities - Total current assets increased to $203.695 million as of March 31, 2024, up from $174.901 million on December 31, 2023, representing a growth of 16.4%[23] - Total assets rose to $301.838 million, compared to $268.641 million at the end of 2023, marking an increase of 12.3%[23] - Total liabilities decreased to $244.927 million as of March 31, 2024, down from $250.246 million at the end of 2023, a reduction of 2.5%[23] - Total shareholders' equity significantly increased to $56.911 million, up from $18.395 million at the end of 2023, representing a growth of 209.5%[23] Cash and Inventory - Cash balance increased to $73.0 million as of March 31, 2024, up by $32.9 million from December 31, 2023[8] - Cash balance increased to $72.980 million as of March 31, 2024, compared to $40.035 million at the end of 2023, a rise of 82.1%[23] - Inventory decreased to $72.489 million from $79.471 million, reflecting a decline of 8.3%[23] Other Financial Metrics - Interest expense for Q1 2024 was $4.381 million, compared to $3.756 million in Q1 2023, an increase of 16.6%[24] - Foreign currency losses amounted to $3.019 million in Q1 2024, contrasting with gains of $0.919 million in Q1 2023, indicating a negative shift[24] Product Launches and Research - The company launched Motiva implants in China and Flora tissue expander in the U.S., with plans for U.S. FDA approval of Motiva expected this year[3] - Four-year data from the Motiva U.S. IDE study presented at The Aesthetic Meeting showed low rates of capsular contracture and rupture, setting a new standard for breast implants[3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-38593 Establishment Labs Holdings Inc. (Exact name of Registrant as specified in its charter) British Virgin Islands 98 ...

Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to loss of $0.55 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 16.84%. A quarter ago, it was expected that this company would post a loss of $0.72 per share when it actually produced a loss of $1.12, delivering a surprise of -55.56%.Over the last four quarters, the co ...

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the fourth quarter and full year ended December 31, 2023 and provided 2024 guidance. Fourth Quarter Highlights and Outlook 2024 revenue guidance of $174 million to $184 million, an increase of 5% to 11% over 2023. Guidance does not include revenue from M ...

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that it has amended its $225 million term loan facility with funds managed by Oaktree Capital Management, L.P. (“Oaktree”). The terms on the two tranches already drawn under the facility, which total $175 million, are unchanged. The remaining two $25 million tranches are amended as follows: Tranche ...

The market expects Establishment Labs Holdings Inc. (ESTA) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is ex ...

Revenue Performance - Revenue for the nine months ended September 30, 2023, was $133.6 million, an increase of $15.7 million or 13.3% compared to $117.9 million in the same period of 2022[199] - Revenue for the three months ended September 30, 2023, was $38.5 million, a slight increase from $38.2 million in the same period of 2022[227] - The Motiva breast implants accounted for over 96% of total revenues for the nine months ended September 30, 2023[211] - The first and second quarters of 2023 resulted in record quarterly revenue, driven by strong demand in the EMEA and Asia-Pacific regions[226] Net Losses and Financial Position - Net losses for the nine months ended September 30, 2023, were $58.0 million, a slight improvement from $61.6 million in the same period of 2022[199] - The net loss for the nine months ended September 30, 2023, was $58.0 million, with significant contributions from changes in operating assets and liabilities[256] - As of September 30, 2023, the accumulated deficit was $339.6 million, with a cash balance of $52.2 million[199] - As of September 30, 2023, the company had cash of $52.2 million, down from $66.4 million at the end of 2022[251] Operating Expenses - Total operating expenses increased by $10.5 million, or 28.7%, to $47.1 million for the three months ended September 30, 2023, compared to $36.6 million in 2022[232][233] - SG&A expenses rose by $8.7 million, or 27.8%, to $40.0 million for the three months ended September 30, 2023, primarily due to increased sales and marketing costs[233] - R&D expenses increased by $1.8 million, or 34.0%, to $7.1 million for the three months ended September 30, 2023, mainly due to higher personnel costs[234] - Total operating expenses for the nine months ended September 30, 2023, were $129.3 million, up from $104.9 million in 2022[243] Cash Flow and Financing Activities - The company reported a net cash used in operating activities of $80.4 million for the nine months ended September 30, 2023, compared to $38.2 million for the same period in 2022[256][257] - Net cash used in investing activities was $19.9 million for the nine months ended September 30, 2023, primarily for capital expenditures related to a new manufacturing facility, compared to $24.4 million in the same period of 2022[259][260] - The company generated $86.2 million in net cash from financing activities for the nine months ended September 30, 2023, mainly from the issuance of common shares, compared to $75.3 million in the same period of 2022[261][262] - The company issued 1,100,000 common shares at a public offering price of $71.50 per share, raising approximately $84.6 million in net proceeds[202] Manufacturing and Product Development - The FDA granted 510(k) clearance for the Motiva Flora SmoothSilk Tissue Expander in October 2023, and the company launched Zen, a next-generation passive RFID technology[200] - The company is expanding manufacturing facilities in Costa Rica, with an estimated $48 million in cash expenditures for the first phase, which will increase manufacturing capacity by approximately 730,000 units per year[208] - Cash paid for capital expenditures on construction in progress related to the new manufacturing facility was $12.3 million for the nine months ended September 30, 2023[259] Future Outlook - The company expects to continue incurring losses in the near term as it invests in sales growth and research and development[209] - The current global macroeconomic environment remains complex, with elevated inflation and interest rates impacting demand for products in the third quarter of 2023[226] - The company anticipates future capital requirements will depend on various factors, including market adoption of products and regulatory activities[254] Accounting Policies - The company has not made any material changes to its critical accounting policies as disclosed in its Annual Report on Form 10-K[267]

Establishment Labs Holdings Inc. (NASDAQ:ESTA) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Raj Denhoy - Chief Financial Officer Juan José Chacón-Quirós - Chief Executive Officer Conference Call Participants Young Li - Jefferies Anthony Petrone - Mizuho Group Josh Jennings - Cowen & Company Sam Eiber - BTIG Neil Chatterji - B. Riley George Sellers - Stephens Operator Good afternoon. Welcome to Establishment Labs’ Second Quarter 2023 Earnings Call. At this time, all partici ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-38593 Establishment Labs Holdings Inc. (Exact name of Registrant as specified in its charter) British V ...